Ultragenyx to Pay $6M Settlement Over Kickback Allegations for Crysvita

Ultragenyx Pharmaceutical has agreed to pay $6 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid, according to the Department of Justice (DOJ). 

DOJ said in a statement that Ultragenyx was paying for free genetic tests and paying a separate fee to receive test result information, all to induce prescriptions of its drug Crysvita.

The drug was approved in 2018 to treat X-linked hypophosphatemia (XLH), a rare form of rickets characterized by low levels of phosphate in the blood. The disease can lead to muscle cramps, weak bones and, in many instances require a genetic test for a definitive diagnosis.

To read the whole story, click here to subscribe.

Related Topics